Lv69
2875 积分 2020-09-19 加入
Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
5小时前
已完结
La citología urinaria preoperatoria mejora la selección de pacientes candidatos a instilación única de mitomicina C
5小时前
待确认
HOME INSTILLATION OF UGN-102 FOR PRIMARY CHEMOABLATION OF RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER: A SINGLE-ARM, OPEN-LABEL, PHASE 3B TRIAL
5小时前
已完结
Treatment Selection for Non-muscle-invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study
5小时前
已关闭
Association of higher thermal dose with improved 5-year recurrence-free survival after locoregional hyperthermia combined with intravesical chemotherapy for non-muscle-invasive bladder cancer
5小时前
已关闭
Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial
5小时前
已关闭
Clinical outcomes of neoadjuvant intravesical mitomycin-C therapy administered immediately prior to TURBT in NMIBC: Over three years of follow-up data from a randomized phase II trial
5小时前
已关闭
MP16-15 INTRAVESICAL ELECTROMOTIVE MITOMYCIN IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE PRIMARY HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER: AN OPEN LABEL, SINGLE ARM, PHASE II STUDY
5小时前
已关闭
Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis
5小时前
已完结
MP71-10 HEAD-TO-HEAD ONCOLOGICAL OUTCOMES COMPARISON OF MITOMYCIN C VS BACILLUS CALMETTE-GUERIN TREATMENT IN INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
5小时前
已关闭
皖公网安备34019202002308
